Abstract: Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Abstract: Topical alcohol-free thermo labile oily foam composition comprising (i) at least one active pharmaceutical ingredient or ectoparasitic active ingredient; (ii) at least about 20% w/w of at least one lipophilic component; (iii) at least about 10% w/w of at least one non-ionic surfactant; (iv) at least about 0.5% w/w of at least one fatty alcohol or fatty acid or ester thereof with melting point above 30° C., and; (v) at least about 7% w/w of propellant selected from propane, butane, isobutane and combinations thereof; said composition optionally comprising at least about 5% to about 70% w/w of a hydrophilic component, optionally comprising up to about 5% w/w hydrogenated oil and optionally comprising a penetration enhancer.

Abstract: Topical alcohol-free thermo labile oily foam composition comprising (i) at least one active pharmaceutical ingredient or ectoparasitic active ingredient; (ii) at least about 20% w/w of at least one lipophilic component; (iii) at least about 10% w/w of at least one non-ionic surfactant; (iv) at least about 0.5% w/w of at least one fatty alcohol or fatty acid or ester thereof with melting point above 30° C., and; (v) at least about 7% w/w of propellant selected from propane, butane, isobutane and combinations thereof; said composition optionally comprising at least about 5% to about 70% w/w of a hydrophilic component, optionally comprising up to about 5% w/w hydrogenated oil and optionally comprising a penetration enhancer.

Abstract: The present invention relates to a topical composition which includes a bioactive drug formulated with silica in the form of microspheres, or drugs in a combination with the silica microspheres in an oily suspension, gel or emulsion. The topical compositions of the invention provide sustained release of a bioactive drug so as to reduce skin irritation.

Abstract: A method for treating a disease or disorder of the skin or scalp of a mammal while simultaneously cleansing the skin or scalp is disclosed. The method includes administering to the skin or scalp a mousse formed from a composition that includes a therapeutically or cosmeceutically effective amount of at least one active pharmaceutical ingredient, 10% to 50% by weight of a cleansing agent selected from the group consisting of anionic surfactants, nonionic surfactants and combinations thereof, a pharmaceutically acceptable mousse-forming carrier that includes a propellant, the propellant being 3% to 50% by weight of the composition, and water being about 40% to about 90% by weight of the composition, waiting a period of time; and rinsing said skin or scalp with water to remove the mousse.

Abstract: The present invention provides a compound of the formula A-L-B (I) or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein A is a psychotropic derivative; L is a linking group comprising two carbon atoms; and B is an alkyl, alkenyl, alkynyl or aralkyl comprising at least one substituent of the formula Q, wherein: the alkyl, alkenyl, alkynyl or aralkyl is optionally substituted with one or more halogens, hydroxyl, cyano, nitro, amino or thiol; and Q is OR6, OC(O)R6, C(O)R6 C(S)R6, CO2R6, C(O)SR6, C(O)NR6R7, C(S)NR6R7, NR6R7, NR6C(O)R7, NR6C(S)R7, NR6C(O)NR7R8, NR6C(S)NR7R8, NR6SO2R7, NR6SO2NR7R8, SR6, SC(O)R6, SC(O)NR6R7, S(O)R6, SO2R6, SO2NR6R7, or NR6SO2R7R8. Also provided is a pharmaceutical composition that includes one or more compounds of the present invention, and methods of therapeutically using and processes for producing such compounds and compositions.

Abstract: Provided is a topical cream composition for the delivery of mometasone furoate comprising low dose mometasone furoate for the treatment of corticosteroid responsive dermatoses. The composition of the present invention can be safely applied over large surface areas of the skin (including areas with wrinkles and/or hair), and can be used therapeutically for extended periods of time (e.g., greater than 3 weeks). Treatment with the composition of the present invention carries reduced and/or fewer side effects compared with commercially available mometasone furoate cream products. The cream composition of the present invention is safe for the use of babies and infants under 2 years old. Additionally provided are methods of preparing and using the composition of the invention.

Abstract: Pharmaceutical, cosmetic and cosmeceutical compositions for topical application, containing, as active ingredients, urea and/or derivatives thereof and alpha-hydroxy acid and/or an ammonium salt thereof, such as ammonium lactate, processes of manufacturing same and use of same in the treatment of medical and cosmetic skin and scalp conditions.